Street Calls of the Week
NEW YORK - Applied DNA Sciences, Inc. (NASDAQ:APDN), currently trading at $4.27 and showing a -98% return over the past year according to InvestingPro data, announced Monday it will change its ticker symbol on the Nasdaq Capital Market from "APDN" to "BNBX" effective at the opening of trading on Tuesday, October 7, 2025.
The biotechnology company stated the new ticker symbol reflects its strategic focus on a BNB-based treasury strategy designed to generate yield and accumulate tokens within the Binance ecosystem. According to the company, it plans to implement a treasury management approach that includes actively managed decentralized finance protocols aimed at enhancing capital efficiency and liquidity.
No action is required from stockholders regarding the ticker symbol change. The company’s common stock will continue to be listed on Nasdaq with the same CUSIP number.
Applied DNA Sciences describes itself as a biotechnology company pursuing a yield-focused BNB digital asset treasury strategy while commercializing nucleic acid production solutions for biopharmaceutical and diagnostics markets.
The announcement was made in a company press release, which contained forward-looking statements regarding the company’s digital asset strategy and potential benefits. These statements involve risks and uncertainties, including the volatile nature of cryptocurrency prices and regulatory developments affecting digital assets. For deeper insights into APDN’s financial health and additional analysis, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with detailed metrics and expert analysis.
In other recent news, Applied DNA Sciences, Inc. has announced significant developments. The company received a follow-on order valued at over $600,000 for its LineaDNA product, which will be utilized in a cancer diagnostic test by a global manufacturer of in vitro diagnostics. This order is part of an existing supply agreement, highlighting ongoing demand for Applied DNA’s products. Additionally, Applied DNA has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company received confirmation from Nasdaq that it meets the $1.00 minimum bid price requirement, resulting in the cancellation of a previously scheduled hearing. Applied DNA is also actively participating in industry conferences, showcasing its nucleic acid production solutions. The company is presenting at the 4th Annual mRNA Process Development and CMC Summit, where it will feature a poster on optimizing mRNA production. These recent developments indicate a period of active engagement and compliance for Applied DNA Sciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.